NCT03943264View on ClinicalTrials.gov

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

September 1, 2021

Conditions
Alzheimer Disease
Interventions
DRUG

XPro1595

XPro1595 will be delivered by subcutaneous injection once a week

Trial Locations (5)

2113

KaRa MINDS, Macquarie Park

3004

Alfred Heath, Melbourne

3128

Eastern Clinical Research Unit, Melbourne

4101

Mater Medical Research Institute, Brisbane

5011

Central Adelaide Local Health Network, Woodville

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

Inmune Bio, Inc.

INDUSTRY

NCT03943264 - A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's | Biotech Hunter | Biotech Hunter